A Phase 1/2 Trial of Perifosine in the Treatment of Non-Small Cell Lung Cancer
Public ClinicalTrials.gov record NCT00399789. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a study of the drug perifosine that consists of 2 parts. The first part of this study was designed to determine the highest dose of perifosine that can be administered to people every week without severe or prolonged nausea, vomiting and diarrhea. This study started with patients taking 900 mg/week and went up to 1800 mg/week. Part I of this study is completed. The MTD had been determined and incorporated in Part II. The goals in Part II are to: 1. Compare the gastrointestinal toxicity of 3 different dose-schedules and 2. Obtain preliminary information on the response rate of perifosine in non-small cell lung cancer.
Study identification
- NCT ID
- NCT00399789
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 121 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 2004 (Type not available)
- Primary completion
- Dec 2010 (Actual)
- Completion
- Dec 2011 (Actual)
- Last update posted
- Feb 22, 2018
2004 – 2011
United States locations
- U.S. sites
- 21
- U.S. states
- 13
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| AOI Pharmaceuticals Investigative Site | Tucson | Arizona | 85704 | — |
| AOI Pharmaceuticals Investigative Site | Pomona | California | 91767 | — |
| AOI Pharmaceuticals Investigative Site | Aventura | Florida | 33180 | — |
| AOI Pharmaceuticals Investigative Site | Hollywood | Florida | 33021 | — |
| AOI Pharmaceuticals Investigative Site | Lakeland | Florida | 33805 | — |
| AOI Pharmaceuticals Investigative Site | Ormond Beach | Florida | 32174 | — |
| AOI Pharmaceuticals Investigative Site | Lawrenceville | Georgia | 30045 | — |
| AOI Pharmaceuticals Investigative Site | Galesburg | Illinois | 61401 | — |
| AOI Pharmaceuticals Investigative Site | New Albany | Indiana | 47150 | — |
| AOI Pharmaceuticals Investigative Site | Grand Rapids | Michigan | 49546 | — |
| AOI Pharmaceuticals Investigative Site | Kalamazoo | Michigan | 49048 | — |
| AOI Pharmaceuticals Investigative Site | Billings | Montana | 59101 | — |
| AOI Pharmaceuticals Investigative Site | Albuquerque | New Mexico | 87109 | — |
| AOI Pharmaceuticals Investigative Site | Albany | New York | 12208 | — |
| AOI Pharmaceuticals Investigative Site | Armonk | New York | 10504 | — |
| AOI Pharmaceuticals Investigative Site | Greenville | South Carolina | 29605 | — |
| AOI Pharmaceuticals Investigative Site | Chattanooga | Tennessee | 37404 | — |
| AOI Pharmaceuticals Investigative Site | Nashville | Tennessee | 37203 | — |
| AOI Pharmaceuticals Investigative Site | Dallas | Texas | 75237 | — |
| AOI Pharmaceuticals Investigative Site | Dallas | Texas | 75246 | — |
| AOI Pharmaceuticals Investigative Site | Tyler | Texas | 75702 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00399789, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 22, 2018 · Synced Sep 30, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00399789 live on ClinicalTrials.gov.